GlassScriptPhysician profile
Leslie K Markle
NPI 1225264443
$9,661.82
in general payments reported to CMS, 2019-2025
26 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $646 · 2021: $982 · 2022: $1,808 · 2023: $1,789 · 2024: $2,258 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,281 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $208 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,280.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $208.12 |
| Education | $198.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,889.88 | 2019-2025 | |
| Janssen Biotech, INC. | $1,808.15 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,072.84 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $953.11 | 2019-2025 | |
| Lilly USA, LLC | $538.79 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $395.99 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $357.33 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Ucb, INC. | $304.33 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $281.72 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $161.86 | 2022-2024 | Adbry |
| Medtronic, INC. | $144.20 | 2022 | |
| Pfizer INC. | $142.16 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $93.15 | 2023-2025 | Zoryve |
| Amgen INC. | $87.77 | 2023-2024 | Otezla |
| Organon LLC | $63.96 | 2025 | Nexplanon, Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $61.06 | 2021 | |
| Incyte Corporation | $50.44 | 2022-2024 | Opzelura |
| Galderma Laboratories, L.P. | $49.67 | 2019-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $44.31 | 2020-2021 | |
| Dermavant Sciences, INC. | $36.57 | 2024 | Vtama |
| Kyowa Kirin, INC. | $28.93 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.23 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $22.02 | 2021 | |
| Botanix Sb INC | $18.18 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $15.88 | 2021 | |
| Epi Health, LLC | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Markle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.